Zoledronic Acid and Angiogenesis

Zoledronic acid and angiogenesis.

To the Editors: In a recent issue of Clinical Cancer Research, Santini and co-workers (1) assert that zoledronic acid (ZA) may inhibit several antiangiogenic-related cascades and its metronomic administration could represent a new potential therapy targeting the endothelial-tumor-stroma behavior. We agree with the authors because better targeting of ZA to cells outside bone could more likely be...

Zometa, INN-zoledronic acid

Zoledronic Acid–Induced Interface Dermatitis

Zoledronic acid (ZA) is a bisphosphonate given intravenously, most commonly for the treatment of postmenopausal osteoporosis. Increase in usage of ZA because it was FDA-approved has resulted in increasing reports of side effects. For the most part, these are systemic. Cutaneous side effects associated with ZA are infrequent and limited to 2 reports of dermatomyositis to date. In both, patients ...

ZOMETA (zoledronic acid) Injection Label

These highlights do not include all the information needed to use ZOMETA safely and effectively. See full prescribing information for ZOMETA. ZOMETA (zoledronic acid) Injection Ready-to-Use Solution for Intravenous Infusion (For Single Use) Concentrate for Intravenous Infusion Initial U.S. Approval: 2001 ----------------------------RECENT MAJOR CHANGES-------------------------Warnings and Preca...

Breast-cancer adjuvant therapy with zoledronic acid.

BACKGROUND Data suggest that the adjuvant use of bisphosphonates reduces rates of recurrence and death in patients with early-stage breast cancer. We conducted a study to determine whether treatment with zoledronic acid, in addition to standard adjuvant therapy, would improve disease outcomes in such patients. METHODS In this open-label phase 3 study, we randomly assigned 3360 patients to rec...